Mr. Rober B. Chess has been the Chairman of the company since 2007. Prior to this, he served as Acting President and Chief Executive Officer for the company; Co-Chief Executive Officer for the company; President and Chief Executive Officer of the company. Mr. Chess has also served as Co-founder and President of Penederm Inc, Chairman of BIO's Emerging Companies Section and Co-Chairman of BIO's Intellectual Property Committee, and as Chairman of Bio Ventures for Global Health. He currently, also serves as the Director for Twist Biosciences, Chairman of Bighat Biosciences and Issio Solutions and as Director of Biotechnology Industry Organization.

Mr. Howard W. Robin has been the President, Chief Executive Officer and Director of the company since 2007. Prior to this, he served as the Chief Executive Officer, President and Director of Sirna Therapeutics, Inc. Previously, he served as the Corporate Vice President and General Manager, Vice President of Finance and Business Development and Chief Financial Officer at Berlex. Mr. Robin spent 20 years at Berlex Laboratories, the U.S. pharmaceutical inclduing Corporate Vice President and General Manager of their U.S form 1991 to 2001.

Mr. Jason Barnard has been the Chief Accounting Officer of the company since January 2025. Prior to this, he served as the Corporate Controller for the company and has served with Blackhawk Network. Mr. Barnard has over 18 years of professional experience.

Mr. Robert Bacci is the Chief People Officer and Head of Quality and Facilities for the company. Prior to this, he has served as an industrial hygienist at multiple firms and as an affiliate faculty member in the MS Program in Organizational Leadership at the Union University and Institute in Cincinnati, Ohio. Mr. Bacci has over 25 years of professional experience.

Ms. Sandra Gardiner has been the Acting Chief Financial Officer of the company since 2023. Prior to this, she served as the Chief Financial Officer, Executive Vice President of Finance and Administration, Secretary and Treasurer of Pulse Biosciences, Inc from November 2019 to December 2022. Ms. Gardiner also serves as a Partner at FLG Partners incluidng Chief Financial officer and Executive Vice President and has in various Chief Financial Officer roles in both domestic and global companies.